Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 50,000 Shares of Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc acquired 50,000 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $700,000.00. Following the purchase, the insider directly owned 829,784 shares of the company’s stock, valued at approximately $11,616,976. This trade represents a 6.41% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 12th, Adar1 Capital Management, Llc acquired 800 shares of Rallybio stock. The stock was acquired at an average price of $13.83 per share, for a total transaction of $11,064.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc acquired 35,101 shares of Rallybio stock. The stock was acquired at an average price of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc acquired 120,804 shares of Rallybio stock. The stock was acquired at an average price of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Stock Up 2.3%

NASDAQ:RLYB opened at $14.35 on Thursday. Rallybio Corporation has a 12-month low of $2.16 and a 12-month high of $15.31. The stock’s 50 day moving average price is $9.70 and its two-hundred day moving average price is $6.93. The firm has a market capitalization of $75.91 million, a price-to-earnings ratio of -5.61 and a beta of -1.10.

Rallybio (NASDAQ:RLYB) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.23 million.

Analyst Ratings Changes

RLYB has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. Wall Street Zen raised Rallybio to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Rallybio currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Rallybio

A number of large investors have recently modified their holdings of RLYB. Citadel Advisors LLC boosted its holdings in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares in the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.